{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:07:02Z","timestamp":1790723222249,"version":"4.1.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Noonan syndrome is frequently associated with an unclear disturbance of GH secretion. Half the individuals with Noonan syndrome carry a heterozygous mutation of the nonreceptor-type protein tyrosine phosphatase, Src homology region 2-domain phosphatase-2 (SHP-2), encoded by PTPN11, which has a role in GH receptor signaling.<\/jats:p>\n               <jats:p>Objective: The objective of this study was to compare GH secretion and IGF-I\/IGF-binding protein-3 (IGFBP-3) levels of the SHP-2 mutation-positive (mut+ group) vs. mutation-negative individuals (mut\u2212 group).<\/jats:p>\n               <jats:p>Design, Setting, and Patients: All children presenting to us with short stature plus at least three typical anomalies of Noonan syndrome or pulmonic stenosis during the last 5 yr (n = 29; 10 females and 19 males) were recruited. Auxological data, dysmorphic features, and cardiac morphology were documented. Hormone levels were measured by RIA. All coding exons of PTPN11 were sequenced after PCR amplification.<\/jats:p>\n               <jats:p>Intervention: A prepubertal subgroup (n = 11) was treated with recombinant human GH (rhGH) to promote growth.<\/jats:p>\n               <jats:p>Results: Sequencing yielded 11 different PTPN11 missense mutations in 16 of the 29 patients (55% mut+). Pulmonic stenosis (81 vs. 15%; P = 0.0007) and septal defects (63 vs. 15%; P = 0.02) were more frequently found in the mut+ group, whereas minor anomalies, cryptorchidism, and learning disabilities were as frequent in the mut+ group as in the mut\u2212 group. The mut+ group was younger at presentation (mean \u00b1 sd, 5.1 \u00b1 2.7 vs. 10.3 \u00b1 5.2 yr; P = 0.002), but not significantly shorter [\u22123.15 \u00b1 0.92 vs. \u22123.01 \u00b1 1.35 height sd score (SDS)]. IGF-I levels (\u22122.03 \u00b1 0.69 vs. \u22121.13 \u00b1 0.89 SDS; P = 0.005) and IGFBP-3 levels (\u22120.92 \u00b1 1.26 vs. 0.40 \u00b1 1.08 SDS; P = 0.006) were significantly lower in the mut+ group. In contrast, GH levels showed a tendency to be higher in the mut+ group during spontaneous secretion at night and arginine stimulation (P \u2265 0.075, not significant). The mean change in height SDS after 1 yr of rhGH therapy (0.043 mg\/kg\u00b7d) was +0.66 \u00b1 0.21 in the mut+ group (n = 8), but +1.26 \u00b1 0.36 in the mut\u2212 group (n = 3; P = 0.007).<\/jats:p>\n               <jats:p>Conclusions: Our data suggest that SHP-2 mutations in Noonan syndrome cause mild GH resistance by a postreceptor signaling defect, which seems to be partially compensated for by elevated GH secretion. This defect may contribute to the short stature phenotype in children with SHP-2 mutations and their relatively poor response to rhGH.<\/jats:p>","DOI":"10.1210\/jc.2005-0995","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T22:28:36Z","timestamp":1126132116000},"page":"5377-5381","source":"Crossref","is-referenced-by-count":135,"title":["PTPN11 Mutations Are Associated with Mild Growth Hormone Resistance in Individuals with Noonan Syndrome"],"prefix":"10.1210","volume":"90","author":[{"given":"G.","family":"Binder","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology Section, University Children\u2019s Hospital, 72076 Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Neuer","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Section, University Children\u2019s Hospital, 72076 Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Ranke","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Section, University Children\u2019s Hospital, 72076 Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. E.","family":"Wittekindt","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Section, University Children\u2019s Hospital, 72076 Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616265383400_R1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archpedi.1968.02100020377005","article-title":"Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease.","volume":"116","author":"Noonan","year":"1968","journal-title":"Am J Dis Child"},{"key":"2020071616265383400_R2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajmg.1320100106","article-title":"A comprehensive scoring system for evaluating Noonan syndrome.","volume":"10","author":"Duncan","year":"1981","journal-title":"Am J Med Genet"},{"key":"2020071616265383400_R3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jpeds.2003.11.032","article-title":"Genotype-phenotype correlations in Noonan syndrome.","volume":"144","author":"Zenker","year":"2004","journal-title":"J Pediatr"},{"key":"2020071616265383400_R4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00441408","article-title":"Noonan syndrome: growth and clinical manifestations in 144 cases.","volume":"148","author":"Ranke","year":"1988","journal-title":"Eur J Pediatr"},{"key":"2020071616265383400_R5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.1991.tb11880.x","article-title":"Noonan\u2019s syndrome: abnormalities of the growth hormone\/IGF-I axis and the response to treatment with human biosynthetic growth hormone.","volume":"80","author":"Ahmed","year":"1991","journal-title":"Acta Paediatr Scand"},{"key":"2020071616265383400_R6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment.","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616265383400_R7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajmg.1320530213","article-title":"Clinical and molecular studies in a large Dutch family with Noonan syndrome.","volume":"53","author":"Van der Burgt","year":"1994","journal-title":"Am J Med Genet"},{"key":"2020071616265383400_R8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"2020071616265383400_R9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/340847","article-title":"PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.","volume":"70","author":"Tartaglia","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2020071616265383400_R10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.ejhg.5200935","article-title":"Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.","volume":"11","author":"Musante","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"2020071616265383400_R11","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1210\/jc.2003-032091","article-title":"Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome.","volume":"89","author":"Yoshida","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616265383400_R12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ajmg.a.30598","article-title":"Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature.","volume":"134","author":"Jongmans","year":"2005","journal-title":"Am J Med Genet A"},{"key":"2020071616265383400_R13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/excr.1999.4668","article-title":"SHP-2 tyrosine phosphatase: signaling one cell or many.","volume":"253","author":"Feng","year":"1999","journal-title":"Exp Cell Res"},{"key":"2020071616265383400_R14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2.","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"2020071616265383400_R15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1210\/mend.14.9.0513","article-title":"Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B.","volume":"14","author":"Stofega","year":"2000","journal-title":"Mol Endocrinol"},{"issue":"Suppl","key":"2020071616265383400_R16","first-page":"1","article-title":"Physical growth of Swiss children from birth to 20 years of age","volume":"52","author":"Prader","year":"1989","journal-title":"First Zurich Longitudinal Study of Growth and Development. Helv Paediatr Acta."},{"key":"2020071616265383400_R17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1651-2227.1991.tb11945.x","article-title":"An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977\u20131981).","volume":"80","author":"Niklasson","year":"1991","journal-title":"Acta Paediatr Scand"},{"key":"2020071616265383400_R18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1530\/eje.0.1500291","article-title":"Central reassessment of GH concentrations measured at local treatment centers in children with impaired growth: consequences for patient management.","volume":"150","author":"Hauffa","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071616265383400_R19","first-page":"1610","article-title":"Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion.","volume":"76","author":"Blum","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616265383400_R20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000073550","article-title":"Insulin-like growth factors and their binding proteins","author":"Blum WF and Schweizer","year":"2003","journal-title":"In: Ranke MB, ed. Diagnostics of endocrine function in children and adolescents. Basel, Switzerland: Karger;"},{"key":"2020071616265383400_R21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2169\/internalmedicine.31.908","article-title":"Noonan syndrome presenting growth hormone neurosecretory dysfunction.","volume":"31","author":"Tanaka","year":"1992","journal-title":"Intern Med"},{"key":"2020071616265383400_R22"},{"key":"2020071616265383400_R23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/JPEM.2002.15.2.175","article-title":"The relationship between clinical severity of Noonan\u2019s syndrome and growth, growth hormone (GH) secretion and response to GH treatment.","volume":"15","author":"Noordam","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl 1","key":"2020071616265383400_R24","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1530\/eje.0.151s011","article-title":"New molecular mechanisms of GH resistance","volume":"151","author":"Rosenfeld","year":"2004","journal-title":"Eur J Endocrinol."},{"key":"2020071616265383400_R25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00467-004-1602-1","article-title":"Molecular physiology, pathology, and regulation of the growth hormone\/insulin-like growth factor-I system.","volume":"20","author":"Woelfle","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"2020071616265383400_R26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1152\/physrev.1996.76.4.1089","article-title":"Mechanism of signaling by growth hormone receptor.","volume":"76","author":"Argetsinger","year":"1996","journal-title":"Physiol Rev"},{"key":"2020071616265383400_R27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1074\/jbc.273.4.2344","article-title":"Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling.","volume":"273","author":"Kim","year":"1998","journal-title":"J Biol Chem"},{"key":"2020071616265383400_R28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1074\/jbc.275.1.599","article-title":"Cytosolic tyrosine dephosphorylation of STAT5.","volume":"275","author":"Yu","year":"2000","journal-title":"J Biol Chem"},{"key":"2020071616265383400_R29","doi-asserted-by":"crossref","first-page":"16520","DOI":"10.1074\/jbc.M210572200","article-title":"Identification of shp-2 as a Stat5a phosphatase.","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071616265383400_R30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/ng1379","article-title":"A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone.","volume":"36","author":"Santos","year":"2004","journal-title":"Nat Genet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/9\/5377\/10777531\/jcem5377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/9\/5377\/10777531\/jcem5377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:16:44Z","timestamp":1594955804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/90\/9\/5377\/2838727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2005-0995","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,1]]}}}